202 related articles for article (PubMed ID: 23469222)
1. Met is the most frequently amplified gene in endometriosis-associated ovarian clear cell adenocarcinoma and correlates with worsened prognosis.
Yamashita Y; Akatsuka S; Shinjo K; Yatabe Y; Kobayashi H; Seko H; Kajiyama H; Kikkawa F; Takahashi T; Toyokuni S
PLoS One; 2013; 8(3):e57724. PubMed ID: 23469222
[TBL] [Abstract][Full Text] [Related]
2. Accumulative copy number increase of MET drives tumor development and histological progression in a subset of ovarian clear-cell adenocarcinomas.
Yamamoto S; Tsuda H; Miyai K; Takano M; Tamai S; Matsubara O
Mod Pathol; 2012 Jan; 25(1):122-30. PubMed ID: 21983935
[TBL] [Abstract][Full Text] [Related]
3. Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patient.
Yamamoto S; Tsuda H; Miyai K; Takano M; Tamai S; Matsubara O
Mod Pathol; 2011 Aug; 24(8):1146-55. PubMed ID: 21478826
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-21 is a candidate driver gene for 17q23-25 amplification in ovarian clear cell carcinoma.
Hirata Y; Murai N; Yanaihara N; Saito M; Saito M; Urashima M; Murakami Y; Matsufuji S; Okamoto A
BMC Cancer; 2014 Nov; 14():799. PubMed ID: 25366985
[TBL] [Abstract][Full Text] [Related]
5. Chromosome 20q13.2 ZNF217 locus amplification correlates with decreased E-cadherin expression in ovarian clear cell carcinoma with PI3K-Akt pathway alterations.
Huang HN; Huang WC; Lin CH; Chiang YC; Huang HY; Kuo KT
Hum Pathol; 2014 Nov; 45(11):2318-25. PubMed ID: 25281027
[TBL] [Abstract][Full Text] [Related]
6. Somatic copy number alterations associated with Japanese or endometriosis in ovarian clear cell adenocarcinoma.
Okamoto A; Sehouli J; Yanaihara N; Hirata Y; Braicu I; Kim BG; Takakura S; Saito M; Yanagida S; Takenaka M; Yamaguchi N; Morikawa A; Tanabe H; Yamada K; Yoshihara K; Enomoto T; Itamochi H; Kigawa J; Matsumura N; Konishi I; Aida S; Aoki Y; Ishii N; Ochiai K; Akiyama T; Urashima M
PLoS One; 2015; 10(2):e0116977. PubMed ID: 25658832
[TBL] [Abstract][Full Text] [Related]
7. Ovarian cancer: new developments in clear cell carcinoma and hopes for targeted therapy.
Yamashita Y
Jpn J Clin Oncol; 2015 May; 45(5):405-7. PubMed ID: 25583423
[TBL] [Abstract][Full Text] [Related]
8. MiR-206 inhibits epithelial ovarian cancer cells growth and invasion via blocking c-Met/AKT/mTOR signaling pathway.
Dai C; Xie Y; Zhuang X; Yuan Z
Biomed Pharmacother; 2018 Aug; 104():763-770. PubMed ID: 29807226
[TBL] [Abstract][Full Text] [Related]
9. Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome.
Huang J; Zhang L; Greshock J; Colligon TA; Wang Y; Ward R; Katsaros D; Lassus H; Butzow R; Godwin AK; Testa JR; Nathanson KL; Gimotty PA; Coukos G; Weber BL; Degenhardt Y
Genes Chromosomes Cancer; 2011 Aug; 50(8):606-18. PubMed ID: 21563232
[TBL] [Abstract][Full Text] [Related]
10. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas.
Bellacosa A; de Feo D; Godwin AK; Bell DW; Cheng JQ; Altomare DA; Wan M; Dubeau L; Scambia G; Masciullo V; Ferrandina G; Benedetti Panici P; Mancuso S; Neri G; Testa JR
Int J Cancer; 1995 Aug; 64(4):280-5. PubMed ID: 7657393
[TBL] [Abstract][Full Text] [Related]
11. PIK3CA overexpression is a possible prognostic factor for favorable survival in ovarian clear cell carcinoma.
Abe A; Minaguchi T; Ochi H; Onuki M; Okada S; Matsumoto K; Satoh T; Oki A; Yoshikawa H
Hum Pathol; 2013 Feb; 44(2):199-207. PubMed ID: 22955107
[TBL] [Abstract][Full Text] [Related]
12. Expression and significance of CD44, CD47 and c-met in ovarian clear cell carcinoma.
Wang H; Tan M; Zhang S; Li X; Gao J; Zhang D; Hao Y; Gao S; Liu J; Lin B
Int J Mol Sci; 2015 Feb; 16(2):3391-404. PubMed ID: 25658794
[TBL] [Abstract][Full Text] [Related]
13. Endometriosis does not confer improved prognosis in ovarian carcinoma of uniform cell type.
Cuff J; Longacre TA
Am J Surg Pathol; 2012 May; 36(5):688-95. PubMed ID: 22498820
[TBL] [Abstract][Full Text] [Related]
14. Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms.
Nakayama K; Nakayama N; Kurman RJ; Cope L; Pohl G; Samuels Y; Velculescu VE; Wang TL; Shih IeM
Cancer Biol Ther; 2006 Jul; 5(7):779-85. PubMed ID: 16721043
[TBL] [Abstract][Full Text] [Related]
15. Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance.
He Y; Wu AC; Harrington BS; Davies CM; Wallace SJ; Adams MN; Palmer JS; Roche DK; Hollier BG; Westbrook TF; Hamidi H; Konecny GE; Winterhoff B; Chetty NP; Crandon AJ; Oliveira NB; Shannon CM; Tinker AV; Gilks CB; Coward JI; Lumley JW; Perrin LC; Armes JE; Hooper JD
Oncogene; 2016 Jan; 35(4):468-78. PubMed ID: 25893298
[TBL] [Abstract][Full Text] [Related]
16. PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma.
Yamamoto S; Tsuda H; Takano M; Tamai S; Matsubara O
Virchows Arch; 2012 Jan; 460(1):77-87. PubMed ID: 22120431
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma.
Rahman M; Nakayama K; Rahman MT; Nakayama N; Ishikawa M; Katagiri A; Iida K; Nakayama S; Otsuki Y; Shih IeM; Miyazaki K
Hum Pathol; 2012 Dec; 43(12):2197-206. PubMed ID: 22705003
[TBL] [Abstract][Full Text] [Related]
18. Targeted next-generation sequencing for molecular diagnosis of endometriosis-associated ovarian cancer.
Er TK; Su YF; Wu CC; Chen CC; Wang J; Hsieh TH; Herreros-Villanueva M; Chen WT; Chen YT; Liu TC; Chen HS; Tsai EM
J Mol Med (Berl); 2016 Jul; 94(7):835-47. PubMed ID: 26920370
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of Rab23 inhibits proliferation, invasion, and metastasis of human ovarian cancer.
Gao L; Zheng M; Guo Q; Nie X; Li X; Hao Y; Liu J; Zhu L; Lin B
Int J Biochem Cell Biol; 2019 Nov; 116():105617. PubMed ID: 31550546
[TBL] [Abstract][Full Text] [Related]
20. RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.
Catenacci DV; Cervantes G; Yala S; Nelson EA; El-Hashani E; Kanteti R; El Dinali M; Hasina R; Brägelmann J; Seiwert T; Sanicola M; Henderson L; Grushko TA; Olopade O; Karrison T; Bang YJ; Kim WH; Tretiakova M; Vokes E; Frank DA; Kindler HL; Huet H; Salgia R
Cancer Biol Ther; 2011 Jul; 12(1):9-46. PubMed ID: 21543897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
